The American Society for Radiation Oncology Workforce Taskforce Review of the United States Radiation Oncology Workforce Analysis.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 07 2023
Historique:
received: 27 02 2023
accepted: 28 02 2023
medline: 5 6 2023
pubmed: 11 3 2023
entrez: 10 3 2023
Statut: ppublish

Résumé

Over the past decade, concerns have arisen in radiation oncology regarding potential workforce supply and demand imbalance. The American Society for Radiation Oncology commissioned an independent analysis in 2022, looking at supply and demand in the United States radiation oncology workforce and projecting future trends for 2025 and 2030. The final report, titled Projected Supply and Demand for Radiation Oncologists in the U.S. in 2025 and 2030, is now available. The analysis included evaluating radiation oncologist (RO) supply (new graduates, exits from the specialty), potential changes in demand (growth of Medicare beneficiaries, hypofractionation, loss of indications, new indications) as well as RO productivity (growth of work relative value units [wRVUs] produced), and demand per beneficiary. The results demonstrated a relative balance between radiation oncology supply and demand for radiation services; the growth in ROs was balanced by the rapid growth of Medicare beneficiaries over the same period. The primary factors driving the model were found to be growth of Medicare beneficiaries and change in wRVU productivity, with hypofractionation and loss of indication having only a moderate effect; although the most likely scenario was a balance of workforce supply and demand, scenarios did demonstrate the possibility of over- and undersupply. Oversupply may become a concern if RO wRVU productivity reaches the highest region; beyond 2030, this is also possible if growth in RO supply does not parallel Medicare beneficiary growth, which is projected to decline and will require corresponding supply adjustment. Limitations of the analysis included uncertainty regarding the true number of ROs, the lack of inclusion of most technical reimbursement and its effect as well as failing to account for stereotactic body radiation therapy. A modeling tool is available to allow individuals to evaluate different scenarios. Moving forward, continued study will be needed to evaluate trends (particularly wRVU productivity and Medicare beneficiary growth) to allow for continued assessment of workforce supply and demand in radiation oncology.

Identifiants

pubmed: 36898417
pii: S0360-3016(23)00207-9
doi: 10.1016/j.ijrobp.2023.02.056
pii:
doi:

Substances chimiques

Reactive Oxygen Species 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

484-490

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Chirag Shah (C)

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: shahc4@ccf.org.

Pranshu Mohindra (P)

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.

Anna Arnone (A)

American Society for Radiation Oncology, Arlington, Virginia.

James Edward Bates (JE)

Department of Radiation Oncology, Emory Healthcare, Atlanta, Georgia.

Malcolm D Mattes (MD)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, RWJ Barnabas Health, New Brunswick, New Jersey.

Shauna Campbell (S)

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

Hiral P Fontanilla (HP)

Princeton Radiation Oncology, Astera Cancer Care, Monroe, New Jersey.

Austin J Sim (AJ)

Department of Radiation Oncology, James Cancer Hospital, Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

Hadley J Sharp (HJ)

Southeast Radiation Oncology, Charlotte, North Carolina.

Patrick Kelly (P)

Orlando Health, Orlando, Florida.

Constantine Mantz (C)

GenesisCare, Fort Myers, Florida.

Thomas Eichler (T)

Department of Radiation Oncology, Massey Cancer Center Virginia Commonwealth University, Richmond, Virginia.

Howard Sandler (H)

Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.

Emma Fields (E)

Department of Radiation Oncology, Massey Cancer Center Virginia Commonwealth University, Richmond, Virginia.

Chelsea C Pinnix (CC)

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Neha Vapiwala (N)

Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Bruce Haffty (B)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, RWJ Barnabas Health, New Brunswick, New Jersey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH